HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
KB 3022
structure given in first source
Also Known As:
1H-Pyrrole-1-acetic acid, 2-(4,5-bis(4-methoxyphenyl)-2-thiazolyl)-, ethyl ester; KB-3022; KBT-3022; ethyl 2-(4,5-bis(4-methoxyphenyl)thiazol-2-yl)pyrrol-1-ylacetate
Networked:
7
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Thiazoles: 392
KB 3022: 7
Pyrroles: 369
KB 3022: 7
Organic Chemicals: 133
Sulfur Compounds: 278
Thiazoles: 392
KB 3022: 7
Related Diseases
1.
Brain Hypoxia (Cerebral Hypoxia)
12/01/1995 - "
These results show that KBT-3022 exerts protective effects against cerebral anoxia and hypoxia and ameliorates delayed neuronal death in the hippocampus.
"
12/01/1995 - "
Protective effect of KBT-3022, a new cyclooxygenase inhibitor, in cerebral hypoxia and ischemia.
"
12/01/1995 - "
The protective effect of KBT-3022 (ethyl 2-[4,5-bis-(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-ylacetate) , a new cyclooxygenase inhibitor, in cerebral hypoxia and ischemia was studied and compared with those of indomethacin and acetylsalicylic acid (ASA).
"
2.
Hypoxia (Hypoxemia)
12/01/1995 - "
These results show that KBT-3022 exerts protective effects against cerebral anoxia and hypoxia and ameliorates delayed neuronal death in the hippocampus.
"
12/01/1995 - "
KBT-3022 (3 and 10 mg/kg, p.o.) and indomethacin (10 mg/kg, p.o.) significantly prolonged the survival time of mice subjected to normobaric hypoxia, while ASA (100 mg/kg, p.o.) had no effect.
"
3.
Thrombosis (Thrombus)
06/01/1995 - "
In this study, we investigated the effects of KBT-3022 (ethyl 2-[4,5-bis(4-methoxyphenyl)-thiazol-2-yl]pyrrol-1-ylacetate) , a potent and long-lasting anti-platelet agent, in several experimental thrombosis models and compared them with those of other anti-platelet drugs.
"
06/01/1995 - "
These results suggest that KBT-3022 may be a useful drug for the treatment and/or prophylaxis of thrombus formation in shunts and aortic thrombosis.
"
06/01/1995 - "
Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis.
"
06/01/1995 - "
However, in a stasis-induced venous thrombosis model in guinea pigs, TP inhibited thrombus formation significantly, but KBT-3022 and ASA were ineffective.
"
06/01/1995 - "
In a model of aortic thrombosis induced by perivascular application of 20% silver nitrate solution, KBT-3022 (1 mg/kg, p.o.) inhibited thrombus formation significantly, ASA (100 mg/kg, p.o.) tended to inhibit it, and TP had no effect.
"
4.
Ischemia
12/01/1995 - "
Protective effect of KBT-3022, a new cyclooxygenase inhibitor, in cerebral hypoxia and ischemia.
"
02/22/1996 - "
KBT-3022 (10 mg/kg) and indomethacin (30 mg/kg) inhibited lactate accumulation in gerbil brain after ischemia and recirculation.
"
12/01/1995 - "
The protective effect of KBT-3022 (ethyl 2-[4,5-bis-(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-ylacetate) , a new cyclooxygenase inhibitor, in cerebral hypoxia and ischemia was studied and compared with those of indomethacin and acetylsalicylic acid (ASA).
"
5.
Venous Thrombosis (Deep-Vein Thrombosis)
06/01/1995 - "
However, in a stasis-induced venous thrombosis model in guinea pigs, TP inhibited thrombus formation significantly, but KBT-3022 and ASA were ineffective.
"
Related Drugs and Biologics
1.
Aspirin (Acetylsalicylic Acid)
2.
Cyclooxygenase Inhibitors
3.
Indomethacin (Indometacin)
4.
Arachidonic Acid (Vitamin F)
5.
Silk
6.
Lactic Acid (Lactate)
7.
Ticlopidine (Ticlid)
8.
Solutions
9.
Silver Nitrate
10.
Platelet Aggregation Inhibitors (Antiplatelet Drugs)
Related Therapies and Procedures
1.
Oral Administration